TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17016955

Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient-fortified beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthelmintic therapy
Number of subjects: 0
Study: 10477530

Group type: EXPERIMENTAL
Intervention: Candesartan (4, 8, or 16 mg)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Candesartan (4 or 8 mg) plus 20 mg of enalapril
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 768
Study: 8698585

Group type: EXPERIMENTAL
Intervention: Newly waived services from hospitals that received a capitated fee
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Services from providers who were paid fee-for-service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving waived services)
Number of subjects: 0
Study: 1769411

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (bacillus Calmette‐Guérin + chemotherapy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Immunotherapy (bacillus Calmette‐Guérin alone)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (specifically for lower limb malignant melanoma)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Immunotherapy (specifically for lower limb malignant melanoma)
Number of subjects: 82
Study: 6280621

Group type: EXPERIMENTAL
Intervention: Unrefined diet (whole foods, 60 g/day dietary fibre)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Refined diet (processed foods, 20 g/day dietary fibre)
Number of subjects: 10
Study: 31342097

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28709832

Group type: EXPERIMENTAL
Intervention: Postoperative roommate with dissimilar surgical status (TKA)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Postoperative roommate with similar surgical status (TKA)
Number of subjects: 520
Study: 25543977

Group type: EXPERIMENTAL
Intervention: Stability shoe
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neutral shoe with prefabricated orthoses
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neutral shoe
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neutral shoe with customised orthoses
Number of subjects: 14
Study: 24598949

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Spontaneous ventilation with T-tube
Number of subjects: 28
Study: 21765354

Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Case-based learning
Number of subjects: 40
Study: 19457248

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFNB‐1b)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 16750497

Group type: EXPERIMENTAL
Intervention: Immediate ADT
Number of subjects: 98

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 98
Study: 15171560

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 7
Study: 11586056

Group type: EXPERIMENTAL
Intervention: Glucose (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9202918

Group type: EXPERIMENTAL
Intervention: Epidural alkalinized lignocaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subarachnoid hyperbaric bupivacaine
Number of subjects: 32
Study: 7768076

Group type: EXPERIMENTAL
Intervention: Intravenous administration of dofetilide (0.5 mg over 30 minutes)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral administration of dofetilide (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous administration of dofetilide (0.5 mg)
Number of subjects: 10
Study: 2213375

Group type: EXPERIMENTAL
Intervention: Maintenance fluid requirements plus replacement of any deficit (mean of 1.42 times calculated maintenance fluid requirements)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluid restriction to two thirds of maintenance requirements (mean of 0.65 times maintenance)
Number of subjects: 19
Study: 496237

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine mixed with dextran 40 solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 40
Study: 31841570

Group type: EXPERIMENTAL
Intervention: Religious affiliation (older women ≥65 years)
Number of subjects: 7524

Group type: EXPERIMENTAL
Intervention: Participation in religious activities more than once per week (older women ≥65 years)
Number of subjects: 7524

Group type: EXPERIMENTAL
Intervention: Weekly religious activities
Number of subjects: 7524

Group type: EXPERIMENTAL
Intervention: Major depressive episode (MDE) prevalence
Number of subjects: 7524
Study: 28299455

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 300 mg twice a day for 60 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (exactly the same appearance as PEA) every 12 hours for 60 days
Number of subjects: 61
Study: 26428224

Group type: EXPERIMENTAL
Intervention: Gastrografin in addition to conservative treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 40
Study: 25455116

Group type: EXPERIMENTAL
Intervention: Clinician-focused intervention (educational sessions, electronic health record-based alerts, and performance feedback)
Number of subjects: 17016

Group type: EXPERIMENTAL
Intervention: Combined intervention (clinician-focused + family-focused)
Number of subjects: 17016

Group type: EXPERIMENTAL
Intervention: Family-focused intervention (automated educational phone calls)
Number of subjects: 17016

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 17016
Study: 22169269

Group type: COMPARATOR
Intervention: Conventional treatment (74 Gy in 37 fractions of 2 Gy)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Hypofractionated treatment (60 Gy in 20 fractions of 3 Gy)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Hypofractionated treatment (57 Gy in 19 fractions of 3 Gy)
Number of subjects: 457
Study: 21058472

Group type: EXPERIMENTAL
Intervention: Needling therapy (local and distal points and points selection according to the differentiation)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Auricular electroacupuncture therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bloodletting at Taiyang Zimai (Extra) or Taiyang (EX‐HN 5) and Ashi points
Number of subjects: 36
Study: 17047932

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: MDMA 1.5 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MDMA 1.5 mg/kg with Fluoxetine 20 mg
Number of subjects: 8
Study: 16143048

Group type: EXPERIMENTAL
Intervention: 15 mg/kg orally
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 15 mg/kg rectally
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 35 mg/kg rectally
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rectal high-dose (35 mg/kg)
Number of subjects: 51
Study: 12490213

Group type: EXPERIMENTAL
Intervention: Rhizophora mangle aqueous bark extract (once a day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rhizophora mangle aqueous bark extract (twice a day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: mercurocrome (twice a day)
Number of subjects: 37
Study: 9009112

Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK-OP) 30 ng/kg stat and 60 ng/kg/hr by infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atropine 0.01 mg/kg stat and 0.01 mg/kg/hr by infusion
Number of subjects: 16
Study: 8363688

Group type: EXPERIMENTAL
Intervention: Shorthand vertical mattress sutures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classic vertical mattress sutures
Number of subjects: 30
Study: 3107289

Group type: EXPERIMENTAL
Intervention: Thyrotropic releasing hormone (TRH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29499742

Group type: EXPERIMENTAL
Intervention: Wiltse's paraspinal approach (group A)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open book laminectomy (group B)
Number of subjects: 47
Study: 26879827

Group type: EXPERIMENTAL
Intervention: Pitolisant 200 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pitolisant 240 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pitolisant 120 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SAD study
Number of subjects: 49

Group type: COMPARATOR
Intervention: TQT study
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SAD study at 240 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: TQT study at 120 mg
Number of subjects: 49
Study: 25437221

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Plasma-Lyte 148
Number of subjects: 2300
Study: 23377597

Group type: EXPERIMENTAL
Intervention: Home healthcare services (HHCS)
Number of subjects: 46
Study: 20692570

Group type: EXPERIMENTAL
Intervention: Mechanical group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Femtosecond group
Number of subjects: 2
Study: 18635463

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 15717846

Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Folate plus Antioxidants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 12384852

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (4 tablets per day for 3 days)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 9972735

Group type: EXPERIMENTAL
Intervention: Experimental videotape about pediatric anesthesia
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control videotape with no medical content
Number of subjects: 85
Study: 7487145

Group type: EXPERIMENTAL
Intervention: 20 micrograms recombinant human interleukin‐2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose (negative control)
Number of subjects: 16
Study: 1840344

Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg/kg i.v.)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Diazepam (0.14 mg/kg i.v.)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (saline, 0.07 ml/kg i.v.)
Number of subjects: 63
Study: 7049312

Group type: EXPERIMENTAL
Intervention: surgery plus a single fraction of 500 rad (5 Gy)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: surgery plus 2000 rad (20 Gy) in 10 equal daily fractions
Number of subjects: 824

Group type: COMPARATOR
Intervention: surgery alone
Number of subjects: 824
Study: 31062189

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) at 2-mA for 20 minutes, 5 days per week for 20 days over the left dorsolateral prefrontal cortex (DLPFC).
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 34
Study: 28536741

Group type: EXPERIMENTAL
Intervention: Community-based intervention targeted at treatment adherence
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (psychotic and bipolar disorders)
Number of subjects: 236
Study: 26754343

Group type: EXPERIMENTAL
Intervention: Sienna+® (superparamagnetic iron oxide particles)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard technique (isotopes ± blue dye)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both methods (Sienna+® and standard technique)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Post-operative complications assessment
Number of subjects: 115
Study: 24405891

Group type: EXPERIMENTAL
Intervention: Tailored interventions to implement the six recommendations for managing depression in the elderly
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study: 22546741

Group type: EXPERIMENTAL
Intervention: Medication adherence assessment using the Morisky Medication Adherence Scale
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patient-related attributes, drug regimen characteristics, health status, patient-provider interaction
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Education and self-rated health
Number of subjects: 302
Study: 19648157

Group type: EXPERIMENTAL
Intervention: Profound haemodilution (haematocrit 19‐21%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard haemodilution (haematocrit 24‐26%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions (haematocrit 19‐21% and 24‐26%)
Number of subjects: 60
Study: 17284731

Group type: EXPERIMENTAL
Intervention: MUFA + EPA/DHA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MUFA + ALA
Number of subjects: 15

Group type: COMPARATOR
Intervention: MUFA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 15
Study: 15195212

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 20
Study: 11274903

Group type: EXPERIMENTAL
Intervention: Trandolapril, 2 mg once daily in the morning
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 18
Study: 9588097

Group type: EXPERIMENTAL
Intervention: Tensitone (7.5% NaCl in 6% dextran 70, Infusia a.s., CR), administered at a dosage of 4 ml/kg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard volume expanders
Number of subjects: 81
Study: 7912576

Group type: EXPERIMENTAL
Intervention: Ibopamine 1%
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ibopamine 1% with Cyclopentolate 1%
Number of subjects: 105

Group type: COMPARATOR
Intervention: Phenylephrine 10% with Cyclopentolate 1%
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Local anaesthetic cases (all groups)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study: 2712981

Group type: EXPERIMENTAL
Intervention: Immediate cold therapy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Simulated therapy (Control)
Number of subjects: 143
Study: 1066150

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) plus dexamethasone (DMT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intrathecal radioactive chromic phosphate (CROP)
Number of subjects: 32
Study: 31274603

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (160 mg of caffeine)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Noncaffeinated energy drink
Number of subjects: 26
Study: 30917863

Group type: EXPERIMENTAL
Intervention: Diabetes medication adherence assessment using the Morisky Medication Adherence Scale (MMAS-8)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Age group 18 to 35 years
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Single marital status
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Fear of diabetes-related complications
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Feeling worse
Number of subjects: 416
Study: 27993829

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg once daily
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg daily
Number of subjects: 594

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg daily
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Filgotinib (both regimens)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Filgotinib and Placebo
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Filgotinib
Number of subjects: 594
Study: 26112449

Group type: EXPERIMENTAL
Intervention: Postcard intervention (sent once a month for eight months)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Postcard intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control
Number of subjects: 184
Study: 24616985

Group type: EXPERIMENTAL
Intervention: Endoscope-assisted resection via retroauricular hairline approach (RHA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional transcervical approach resection
Number of subjects: 25
Study: 21571233

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 114
Study: 18443343

Group type: EXPERIMENTAL
Intervention: Betamethasone (4 mg)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 380
Study: 17213596

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg per day
Number of subjects: 48
Study: 12874677

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micro g administered as an intravenous bolus)
Number of subjects: 11
Study: 10743822

Group type: EXPERIMENTAL
Intervention: Controlled release codeine (50 mg every 12 h at baseline, escalated to 159 mg every 12 h at final assessment)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Controlled release codeine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9206057

Group type: EXPERIMENTAL
Intervention: Captopril (n = 478, Group I)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Conventional treatment (n = 344, Group II)
Number of subjects: 822
Study: 1393033

Group type: EXPERIMENTAL
Intervention: Anistreplase 30 units intravenously
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 2996028

Group type: EXPERIMENTAL
Intervention: ACTH 4‐9 analog (ORG 2766) 40 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31088728

Group type: EXPERIMENTAL
Intervention: DM + CKD
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: DM + CVD
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: DM + CVD + CKD
Number of subjects: 1046
Study: 30232113

Group type: EXPERIMENTAL
Intervention: High-flow heated and humidified nasal oxygen (HFHO) therapy
Number of subjects: 242

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 242
Study: 27152759

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at 0.25 μg/kg/hour for 96 hours starting 1 hour after portal venous reperfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion
Number of subjects: 0
Study: 23841569

Group type: EXPERIMENTAL
Intervention: Insulin detemir (IDet)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 36
Study: 22592665

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg per day increased to 300 mg per day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB) group with amlodipine increased from 7.5 mg to 10 mg per day
Number of subjects: 64
Study: 20348368

Group type: EXPERIMENTAL
Intervention: EPA-FFA (2 g daily for 6 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 18547853

Group type: EXPERIMENTAL
Intervention: NIOX MINO
Number of subjects: 70
Study: 15805751

Group type: EXPERIMENTAL
Intervention: Long-arm casting (n=44)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Short-arm casting (n=39)
Number of subjects: 83
Study: 11818294

Group type: EXPERIMENTAL
Intervention: History of unwanted sexual activity during childhood
Number of subjects: 2676
Study: 10599356

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 7551841

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 1827016

Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine (isradipine SR) 5 mg/day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine (isradipine SR) 10 mg/day
Number of subjects: 73
Study: 6953986

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 45 mg/sq m
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 30 mg/sq m
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) 30 mg/sq m
Number of subjects: 0
Study: 31479005

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (9-month curriculum, daily after school)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait list control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study: 30887570

Group type: EXPERIMENTAL
Intervention: β-D-Mannuronic acid (1000 mg/d, 2 capsules orally for 8 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Evaluation of tumor markers (carcinoembryonic antigen and cancer antigen 15-3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: β-D-Mannuronic acid therapy
Number of subjects: 48
Study: 27471798

Group type: EXPERIMENTAL
Intervention: ANA intervention (education and feedback)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 20
Study: 25227774

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 88

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 88

Group type: COMPARATOR
Intervention: Comparison between Propofol and Isoflurane
Number of subjects: 88
Study: 23845016

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study: 21873264

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg plus daily glucocorticosteroids
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo plus daily glucocorticosteroids
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Infliximab plus glucocorticosteroids
Number of subjects: 44
Study: 20008203

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (warfarin) for patients with antiphospholipid antibodies and venous thromboembolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin or warfarin for ischemic stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic-dose heparin and aspirin for women with recurrent pregnancy loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy in patients with APS-associated thrombocytopenia
Number of subjects: 0
Study: 16355282

Group type: EXPERIMENTAL
Intervention: Oral alendronate 1 mg/kg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous pamidronate 3 mg/kg/4 months
Number of subjects: 18